Promising news for PrEP users & the fight against HIV
rare result for any clinical trial. In this instance, researchers studied over 2,000 young women in South Africa and Uganda.
Both countries have high infection rates. Subscribe to our newsletter for a refreshing cocktail (or mocktail) of LGBTQ+ entertainment and pop culture, served up with a side of eye-candy.Current PrEP doesn’t work as well in women as it does in gay men.
This is because the medication’s efficiency is tied to maintaining a sufficient concentration in crucial body tissues. For example, higher concentrations of Truvada accumulate in rectal tissue compared to the vagina.
Throughout the lenacapavir study, none of the female, African trial participants contracted HIV. This makes the twice-yearly injection more effective than a daily pill of Truvada or Descovy for women.
